Pacira | PCRX - Des Atouts





Des Atouts Changement Date
Astellas Pharma JPY 3.69T 125.48B 2026-06
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Cara Therapeutics USD 25.82M 6.26M 2026-03
Coherus Biosciences USD 191.18M 74.84M 2026-06
Heron Therapeutics USD 252.26M 6.05M 2026-06
Ironwood Pharmaceuticals USD 434.57M 37.66M 2026-03
J&J USD 201.06B 167M 2026-06
Ligand Pharmaceuticals USD 2.19B 653.77M 2026-06
Nektar Therapeutics USD 763.27M 482.86M 2026-03
Novo Nordisk DKK 594.94B 35.72B 2026-06
Omeros USD 200.57M 34.59M 2025-06
Pacira USD 1.24B 35.44M 2026-06
Perrigo USD 7.61B 373.8M 2026-06
Pfizer USD 201.13B 6.49B 2026-06
Supernus Pharmaceuticals USD 1.43B 72.62M 2026-06
Teva Pharmaceutical Industries USD 39.86B 183M 2026-06
Xeris Pharmaceuticals USD 411.9M 19.89M 2026-06
Zoetis USD 15.08B 77M 2026-06